Detalhe da pesquisa
1.
Risk and outcomes of COVID-19 in patients with multiple sclerosis.
Eur J Neurol
; 28(11): 3712-3721, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152073
2.
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
CNS Drugs
; 38(3): 231-238, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418770
3.
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
CNS Drugs
; 34(12): 1275-1286, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33226562